Carregant...
Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab
Patients with metastatic melanoma who progress on ipilimumab can clearly derive benefit to subsequent anti-PD-1 (programmed death-1). However, patients experience heterogeneous outcomes with ipilimumab, including rapid or delayed progression, and it is unclear whether patterns of ipilimumab progress...
Guardat en:
| Publicat a: | Cancer Immunol Res |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4940026/ https://ncbi.nlm.nih.gov/pubmed/27197063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0281 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|